Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.
Friedman LS, Farmer JM, Perlman S, Wilmot G, Gomez CM, Bushara KO, Mathews KD, Subramony SH, Ashizawa T, Balcer LJ, Wilson RB, Lynch DR.
Friedman LS, et al. Among authors: lynch dr.
Mov Disord. 2010 Mar 15;25(4):426-32. doi: 10.1002/mds.22912.
Mov Disord. 2010.
PMID: 20063431
Free PMC article.